Regulating human stem cell research and therapy in low- and middle-income countries: Malaysian perspectives
Regulating human stem cell research and therapy in low- and middle-income countries: Malaysian perspectives
复制标题
DOI：
10.1080/14636778.2017.1415137
复制
发表时间：
2018-01-01
影响因子：
1.8
通讯作者：
Kaye, Jane
中科院分区：
文献类型：
--
作者：
Aziz, Mohammad Firdaus Bin Abdul;Morrison, Michael;Kaye, Jane
许多新兴大国，如印度、中国、阿根廷、新加坡和巴西，都在投资干细胞技术，加入了该领域的传统领先者的行列，如英国、德国、美国和日本。马来西亚也正在进入这一领域，因为使用干细胞技术可能带来潜在的医疗和经济利益。与其他国家一样，马来西亚面临的挑战是如何以道德的方式鼓励科学进步和创新，同时确保再生疗法有一个安全和可进入的市场。本文报道了与当地利益相关者的半结构化访谈的研究结果，以调查他们如何看待和评估马来西亚目前的人类干细胞研究监管框架，以及如果国家继续其目前的监管方法可能会面临什么风险。
Many rising powers such as India, China, Argentina, Singapore, and Brazil are investing in stem cell technology, joining the traditional leaders in the field, such as the UK, Germany, USA, and Japan. Malaysia is also entering this sector because of the potential medical and economic benefits that the use of stem cell technologies could provide. Like other countries, Malaysia faces the challenge of how to encourage scientific progress and innovation in an ethical manner while at the same time ensuring a safe and accessible market for regenerative therapies. This paper reports on the research findings of semi-structured interviews with local stakeholders to investigate how they perceived and evaluated the current regulatory framework for human stem cell research in Malaysia, and what might be at stake if the state continues with its current regulatory approach.